Corsair Pharma is developing transformative solutions to improve the therapeutic profile of medications and provide superior treatment options for patients. The company is focused on the development of novel prodrugs of treprostinil to treat patients with PAH using a once-daily transdermal patch.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/20/23 | $23,000,000 | Series B |
Junson Capital Midas Capital New Rhein Healthcare Investors  Plaisance Capital Management Primavera Capital | undisclosed |
